{
    "nct_id": "NCT03113825",
    "official_title": "An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery",
    "inclusion_criteria": "* DCIS or Stage I-III primary invasive carcinoma of the breast\n* Primary surgical treatment is lumpectomy + SLNB or ALND --or-- mastectomy + ALND\n* Signed written informed consent\n* At least 18 years of age\n* ECOG performance status 0 to 2\n* Life expectancy of at least 6 months\n* Total bilirubin ≤ 2 mg/dL\n* AST/SGOT and ALT/SGPT ≤ 2.5 X ULN\n* Negative serum pregnancy test and using medically acceptable form of contraception if of child bearing potential\n* LVEF within normal limits if patient received prior anthracycline therapy [Period 1].\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Recurrent ipsilateral breast cancer\n* Prior neoadjuvant chemotherapy, endocrine therapy, or biologic therapy for current breast cancer [Period 2]\n* Prior neoadjuvant chemo or biologic therapy for current breast cancer within 4 weeks prior to planned surgery [Period 1]\n* Open surgery in ipsilateral breast within 1 year.\n* Prior malignancy, other than breast cancer, active within the last 6 months\n* Prior radiation therapy to the chest [Period 2]\n* Radiation therapy to ipsilateral breast [Period 1]\n* Abnormal cardiac rhythm not controlled with medication; Hx of stroke within 1 year; Hx of coronary events and/or heart failure within 1 year.\n* Diagnosis of autoimmune disorder, including RA, SLE, or Sjogren's syndrome\n* Hx of drug-related anaphylactic reactions, severe allergic reactions related to drug; active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma requiring oral corticosteroids.\n* Hx of drug-induced acute tubular necrosis.\n* Chronic renal failure or current evidence of moderate to severe renal impairment.\n* Current diagnosis of any other active or clinically significant nonbreast cancer\n* Received systemic investigational drug within 6 weeks prior to AVB-620 administration or has received AVB-620 previously.\n* Pregnant or breast feeding or plans to become pregnant within 6 months of AVB-620 administration.\n* Unresolved acute toxicity from prior anticancer therapy",
    "miscellaneous_criteria": ""
}